Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates
- Accelerate Diagnostics (AXDX) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $1.40 per share a year ago.
- 03/28/2024
|
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results
- TUCSON, Ariz. , March 28, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and year ended December 31, 2023.
- 03/28/2024
|
Accelerate Diagnostics Scheduled Call to Review 2023 Fourth Quarter and Full Year Results.
- TUCSON, Ariz. , March 7, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, March 28, 2024, at 4:30 p.m.
- 03/07/2024
|
Accelerate Diagnostics Announces Pricing of Approximately $15 Million Public Offering and Private Placement
- TUCSON, Ariz. , Jan. 19, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) (the "Company") today announced the pricing of an underwritten public offering consisting of 6,860,659 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, and for certain investors in lieu thereof, pre-funded units, each consisting of one pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock.
- 01/19/2024
|
Accelerate Diagnostics Announces Launch of Proposed Public Offering
- TUCSON, Ariz. , Jan. 16, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) (the "Company") today announced the launch of a proposed underwritten public offering of 4,500,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, or for certain investors, pre-funded units in lieu thereof, with each pre-funded unit consisting of one-pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock, pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission (the "SEC").
- 01/16/2024
|
Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2023 Results
- TUCSON, Ariz. , Jan. 7, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) (Accelerate), an in vitro diagnostics company dedicated to providing services that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections, today announced certain preliminary, unaudited results for the quarter and year ended December 31, 2023.
- 01/07/2024
|
Accelerate Diagnostics (AXDX) Expands in In Vitro Diagnostics
- Accelerate Diagnostics' (AXDX) Arc system eliminates the need for overnight culture incubation, drastically reducing the wait time for identification results.
- 11/29/2023
|
Accelerate Diagnostics Announces Collaboration for the Use of the Arc™ System in Combination With Bruker´s MALDI Biotyper®
- Working together to bring rapid, automated microbial identification directly from positive blood culture samples TUCSON, Ariz. , Nov. 27, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an innovator of rapid in vitro diagnostics in microbiology, announced the signing of a collaboration and quality agreement with Bruker Corporation (NASDAQ: BRKR), the provider of the market-leading MALDI Biotyper system for microbial identification.
- 11/27/2023
|
Accelerate Diagnostics (AXDX) Loses -25.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Accelerate Diagnostics (AXDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 11/22/2023
|
Accelerate Diagnostics, Inc. (AXDX) Q3 2023 Earnings Call Transcript
- Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Laura Pierson - IR Officer Jack Phillips - President & Chief Executive Officer David Patience - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Albert Hu - Craig-Hallum Operator Good day, and welcome to the Accelerate Diagnostics, Inc. 2023 Third Quarter Results Conference Call. All participant's will be in listen-only mode.
- 11/09/2023
|
Accelerate Diagnostics Scheduled Call to Review 2023 Third Quarter Results.
- TUCSON, Ariz. , Oct. 30, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, November 9, 2023, at 4:30 p.m.
- 10/30/2023
|
Accelerate Diagnostics (AXDX) Moves 12.7% Higher: Will This Strength Last?
- Accelerate Diagnostics (AXDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 10/03/2023
|
Accelerate Diagnostics, Inc. (AXDX) Q2 2023 Earnings Call Transcript
- Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q2 2023 Earnings Conference Call August 10, 2023 4:00 PM ET Company Participants Laura Pierson - IR Officer Jack Phillips - CEO, President & Director David Patience - CFO, Principal Financial Officer & Principal Accounting Officer Conference Call Participants Conner Chamberlain - Craig-Hallum Dustin Scaringe - William Blair & Company Operator Good day, and welcome to the Accelerate Diagnostics, Inc. 2023 Q2 Results Conference Call. [Operator Instructions].
- 08/10/2023
|
Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates
- Accelerate Diagnostics (AXDX) came out with a quarterly loss of $2.36 per share versus the Zacks Consensus Estimate of a loss of $1.50. This compares to loss of $2.40 per share a year ago.
- 08/10/2023
|
Is Accelerate Diagnostics (AXDX) Stock Outpacing Its Medical Peers This Year?
- Here is how Accelerate Diagnostics (AXDX) and BellRing Brands (BRBR) have performed compared to their sector so far this year.
- 06/29/2023
|
Is Accelerate Diagnostics (AXDX) Outperforming Other Medical Stocks This Year?
- Here is how Accelerate Diagnostics (AXDX) and Cognition Therapeutics, Inc. (CGTX) have performed compared to their sector so far this year.
- 05/23/2023
|
Accelerate Diagnostics, Inc. (AXDX) Q1 2023 Earnings Call Transcript
- Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Laura Pierson - Investor Relations Jack Phillips - President & Chief Executive Officer David Patience - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Operator Good day, and welcome to the Accelerate Diagnostics Incorporated 2023 Q1 Results Conference Call. All participants will be in listen-only mode.
- 05/11/2023
|
Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates
- Accelerate Diagnostics (AXDX) came out with a quarterly loss of $0.17 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.25 per share a year ago.
- 05/11/2023
|
Forget Bargain Hunting, Buy 5 Stocks With Rising P/E
- Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Disney (DIS), Casey's General Stores (CASY), OpGen (OPGN), Accelerate Diagnostics (AXDX) and Nektar Therapeutics (NKTR).
- 04/18/2023
|
Accelerate Diagnostics (AXDX) Upgraded to Buy: What Does It Mean for the Stock?
- Accelerate Diagnostics (AXDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 04/03/2023
|
Accelerate Diagnostics, Inc. (AXDX) Q4 2022 Earnings Call Transcript
- Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET Company Participants Laura Pierson - IR Jack Phillips - President and CEO Steve Reichling - outgoing-CFO David Patience - incoming-CFO Conference Call Participants Alex Nowak - Craig-Hallum Dustin Scaringe - William Blair Operator Good afternoon, and welcome to the Accelerate Diagnostics Fourth Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.
- 03/29/2023
|
Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates
- Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 12.50% and 0.93%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/29/2023
|
Accelerate Diagnostics, Inc. (AXDX) Q3 2022 Earnings Call Transcript
- Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Laura Pierson - IR Officer Jack Phillips - CEO, President & Director Steve Reichling - CFO Conference Call Participants Andrew Brackmann - William Blair & Company Connor Stevenson - Craig-Hallum Operator Good afternoon, and welcome to the Accelerate Diagnostics Inc. Third Quarter 2022 Earnings Call. [Operator Instructions].
- 11/14/2022
|
Accelerate Diagnostics, Inc.'s (AXDX) CEO Jack Phillips on Q2 2022 Results - Earnings Call Transcript
- Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Laura Pierson - Investor Relations Jack Phillips - President and Chief Executive Officer Steve Reichling - Chief Financial Officer Conference Call Participants Brian Weinstein - William Blair Operator Good day, and welcome to the Accelerate Diagnostics Second Quarter 2022 Earnings Call. All participants will be in listen-only mode.
- 08/15/2022
|
Best Penny Stocks to Buy Now? 3 to Watch This Week
- Can these penny stocks make gains this month? The post Best Penny Stocks to Buy Now?
- 06/07/2022
|
Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q1 2022 Results - Earnings Call Transcript
- Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Laura Pierson – Investor Relations Jack Phillips – Chief Executive Officer Steve Reichling – Chief Financial Officer Conference Call Participants Operator Good day, and welcome to the Accelerate Diagnostics, Inc. 2022 First Quarter Results Conference Call. All participants will be in listen-only mode.
- 05/16/2022
|
Accelerate Diagnostics (AXDX) Reports Q1 Loss, Tops Revenue Estimates
- Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 21.88% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/16/2022
|
Accelerate Diagnostics' (AXDX) CEO Jack Phillips on Q4 2021 Results - Earnings Call Transcript
- Accelerate Diagnostics' (AXDX) CEO Jack Phillips on Q4 2021 Results - Earnings Call Transcript
- 03/08/2022
|
Accelerate Diagnostics (AXDX) Reports Q4 Loss, Tops Revenue Estimates
- Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 23.33% and 3.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/08/2022
|
Accelerate Diagnostics (AXDX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
- Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/15/2022
|
Penny Stocks To Buy Now According To Insiders In December 2021
- Insiders are buying these penny stocks during "tax loss season" The post Penny Stocks To Buy Now According To Insiders In December 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/20/2021
|
Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q3 2021 Results - Earnings Call Transcript
- Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q3 2021 Results - Earnings Call Transcript
- 11/09/2021
|
Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates
- Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 57.14% and -11.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/09/2021
|
Are These 2 Companies Next for Short Squeezes?
- SmileDirectClub and Accelerate Diagnostics are super cheap right now, with very high short positions. Here's why the shorts might rupture.
- 10/21/2021
|
Accelerate Diagnostics Announces Agreements to Exchange Approximately $51 Million in Principal Amount of Its 2.50% Convertible Senior Notes due 2023 for Common Stock
- TUCSON, Ariz., Sept. 23, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 2.50% Convertible Senior Notes due 2023 (the "Notes").
- 09/23/2021
|
Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q2 2021 Results - Earnings Call Transcript
- Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q2 2021 Results - Earnings Call Transcript
- 08/08/2021
|
Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates
- Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -2.86% and -12.37%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/05/2021
|
Accelerate Diagnostics (AXDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/29/2021
|
Accelerate Diagnostics Schedules Call to Review 2nd Quarter 2021 Results
- TUCSON, Ariz., July 15, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. announced today that management will host a conference call on Thursday, August 5, 2021, at 4:30 p.m.
- 07/15/2021
|
Up 6% in June, Is Accelerate Diagnostics a Good Buy Now?
- Investors were encouraged by a recent award the company received in the effort to diagnose and treat sepsis more rapidly.
- 07/08/2021
|
Accelerate Diagnostics Launches a Fast Antimicrobial Susceptibility Test for Use with Existing ID Systems in the United States
- TUCSON, Ariz., July 7, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced the launch of a new IVD configuration of its Accelerate PhenoTest® BC kit in the United States.
- 07/07/2021
|
New Accelerate Pheno® Landmark Study Validates Important Clinical Benefits to Be Presented at ECCMID 2021
- TUCSON, Ariz., June 30, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that it will have 3 data presentations from its Improving Outcomes and Antibiotic Stewardship (IOAS) Study at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) to be held July 9–12, 2021.
- 06/30/2021
|
New Strong Sell Stocks for June 2nd
- BEP, AXDX, FURY, KBAL, and LUNA have been added to the Zacks Rank #5 (Strong Sell) List on June 2, 2021
- 06/02/2021
|
New Strong Sell Stocks for May 20th
- AXDX, CRIS, FSTR, GO, and PRLB have been added to the Zacks Rank #5 (Strong Sell) List on May 20, 2021
- 05/20/2021
|
Accelerate Diagnostics to Participate in William Blair 41st Annual Growth Stock Conference on June 3, 2021
- TUCSON, Ariz., May 19, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that Chief Executive Officer, Jack Phillips, and Chief Financial Officer, Steve Reichling, will present virtually at the William Blair 41st Annual Growth Stock Conference on Thursday, June 3, 2021 at 12:00 p.m.
- 05/19/2021
|
New Strong Sell Stocks for May 14th
- AXDX, CDR, FPAY, GCI, and IRTC have been added to the Zacks Rank #5 (Strong Sell) List on May 14, 2021
- 05/14/2021
|
Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q1 2021 Results - Earnings Call Transcript
- Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q1 2021 Results - Earnings Call Transcript
- 05/06/2021
|
Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates
- Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -24.24% and -29.07%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/06/2021
|
Accelerate Diagnostics Reports First Quarter 2021 Financial Results
- TUCSON, Ariz., May 6, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the first quarter for the period ended March 31, 2021.
- 05/06/2021
|
Accelerate Diagnostics to Host Call to Review First Quarter 2021 Results
- TUCSON, Ariz., May 5, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) announced today that management will host a conference call on Thursday, May 6, 2021 at 4:30 p.m.
- 05/05/2021
|
Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q4 2020 Results - Earnings Call Transcript
- Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q4 2020 Results - Earnings Call Transcript
- 02/23/2021
|
Accelerate Diagnostics Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results
- TUCSON, Ariz., Jan. 12, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced preliminary financial results for the fourth quarter and full year ending December 31, 2020. Highlights for the fourth quarter and full-year 2020 are presented below. 2020 Fourth...
- 01/12/2021
|
Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q3 2020 Results - Earnings Call Transcript
- Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q3 2020 Results - Earnings Call Transcript
- 11/07/2020
|
Accelerate Diagnostics (NASDAQ:AXDX) Upgraded to Sell by BidaskClub
- Accelerate Diagnostics (NASDAQ:AXDX) was upgraded by BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Thursday, BidAskClub reports. A number of other equities analysts also recently issued reports on AXDX. Zacks Investment Research downgraded shares of Accelerate Diagnostics from a “buy” rating to a […]
- 10/15/2020
|
Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen
- INDIANAPOLIS, Oct. 8, 2020 /PRNewswire via COMTEX/ --
INDIANAPOLIS, Oct. 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY)...
- 10/08/2020
|
Merck Announces Week 96 Data from Phase 2b Study Evaluating Islatravir in Combination With Doravirine in Adults With HIV-1 Infection
- Merck Announces Week 96 Data from Phase 2b Study Evaluating Islatravir in Combination with Doravirine in Adults with HIV-1 Infection
- 10/08/2020
|
Ast Groupe :
Résultats semestriels 2020 | Zone bourse
|
AST Private Company Solutions Partners with Wealthramp, the Nation's Top Fiduciary Advisor Referral Service, to Offer Access to Unbiased Financial Advice
- AST Private Company Solutions (PCS) announced a strategic partnership with leading financial advisor referral company Wealthramp.
- 09/24/2020
|
Ast Groupe :
Résultats semestriels 2020 | Zone bourse
|
Marinus Announces One-for-Four Reverse Stock Split
- Marinus Pharmaceuticals announced that it will effect a one-for-four reverse stock split of its common stock at 5:00 pm ET today.
- 09/22/2020
|
Global Medical Coatings (Active, Passive) Markets Report 2020-2025 - ResearchAndMarkets.com
|
Accelerate Diagnostics Announces Emergency Use Authorization for Covid-19 Antibody Test
- This new testing platform will speed up health checks by determining whether asymptomatic people have COVID-19 antibodies in 30 minutes.
- 08/19/2020
|
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs
- Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) * Avenue Therapeutics Inc (NASDAQ: ATXI) * Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) * DarioHealth Corp (NASDAQ: DRIO) * iTeos Therapeutics Inc (NASDAQ: ITOS) * Merit Medical Systems, Inc. (NASDAQ: MMSI) * Natera Inc (NASDAQ: NTRA) * Nurix Therapeutics Inc (NASDAQ: NRIX) * Otonomy Inc (NASDAQ: OTIC) * Pacific Biosciences of California Inc (NASDAQ: PACB) * Pacira Biosciences Inc (NASDAQ: PCRX) * PDL BioPharma Inc (NASDAQ: PDLI) * Principia Biopharma Inc (NASDAQ: PRNB) * Qiagen NV (NYSE: QGEN) * Shockwave Medical Inc (NASDAQ: SWAV) * Silk Road Medical Inc (NASDAQ: SILK) * Syros Pharmaceuticals Inc (NASDAQ: SYRS)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 18) * Acorda Therapeutics Inc (NASDAQ: ACOR) * Alector Inc (NASDAQ: ALEC) * Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) * Interpace Biosciences Inc (NASDAQ: IDXG)(announced receipt of letters from recently departed employees regarding billing and compliance issues) * Iterum Therapeutics PLC (NASDAQ: ITRM) * NanoVibronix Inc (NASDAQ: NAOV) * Poseida Therapeutics, Inc. (NASDAQ: PSTX)( announced clinical hold on its Phase 1 prostate cancer study) * Predictive Oncology Inc (NASDAQ: POAI) * Recro Pharma Inc (NASDAQ: REPH) * Unity Biotechnology Inc (NASDAQ: UBX)Stocks In Focus Venrock Reports Purchase of 451K Unum Shares Unum Therapeutics Inc (NASDAQ: UMRX) shares advanced after Venrock Healthcare Partners III L.P. said in a filing it has purchased 451,000 shares of Unum's common stock in a series of transactions effected between Aug. 14 and Aug. 18, bringing the total number of shares owned by the fund to 4.355 millionThe stock climbed 16.24% to $3.15 in after-hours trading.Gilead's Filgotinib Face Rejection at the FDA Altar Gilead Sciences, Inc. (NASDAQ: GILD) said the FDA has issued a complete response letter for its NDA for filgotinib, an investigational treatment for moderately to severely active rheumatoid arthritis. The agency has sought data from the MANTA and MANTA-RAy studies, which look into whether filgotinib has an impact of sperm parameters, before completing the review, while also expressing concerns regarding the overall benefit/risk profile of the filgotinib 200 mg dose. Top-line results from the two additional studies which the FDA has requested is expected to be released in the first half of 2021, Gilead said.Gilead is partnering with GALAPAGOS NV/S ADR (NASDAQ: GLPG) for the development of filgotinib.In pre-market trading, Gilead shares were down 6.02% to $64.90.J&J to Buy Momenta For $6.5B In Cash Johnson & Johnson (NYSE: JNJ) said it has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) for $52.50 per share in an all-cash transaction, implying a fully-diluted equity value of $6.5 billion. The agreement was unanimously approved by boards of both companies.Momenta shares were jumping 68.48% to $51.91.Sorrento Terminates Services of CFO; Patent Filed For A Competing Saliva-based COVID-19 Test Sorrento Therapeutics Inc (NASDAQ: SRNE) said in a filing that it has terminated services of CFO Jiong Shao as CFO, effective immediately, and has appointed Najjam Asghar, who was serving as the principal financial officer and principal accounting officer, to the role of CFO on an interim basis.Separately, Switerzland's Achiko said it has filed a provisional patent over the technology involved in a non-intrusive and affordable novel saliva COVID-19 test kit, named Gumnuts. The company holds the exclusive commercialization rights for the test. Clinical trials are to begin shortly and the test could be made commercially available by the end of 2020, Achiko said. Incidentally, Sorrento had licensed a rapid saliva test kit from the Columbia University in late July.Sorrento shares tumbled 13.52% to $10.62 in after-hours trading.Accelerate Diagnostics Gets Emergency Use Authorization For COVID-19 Antibody Testing System Accelerate Diagnostics Inc (NASDAQ: AXDX) and ioCheck, Inc., a privately-held San Francisco-based company, said the FDA has issued an emergency use authorization for the BioCheck SARS-CoV-2 IgM and IgG Combo Test and fully-automated MS-Fast instrument.Accelerate has a collaboration agreement with ioCheck to commercialize the serology-based testing platform.View more earnings on IBBThe MS-Fast system and BioCheck SARS-CoV-2 chemiluminescence tests are capable of processing human serum samples in 30 minutes to detect antibodies that indicate recent or prior COVID-19 infection, Accelerate said.The stock gained 9.84% to $16.30 in after-hours trading.Centogene Begins to Offer Walk-in COVID-19 Test Facility at Hamburg Airport Centogene NV (NASDAQ: CNTG) announced the opening of its new walk-in COVID-19 test facility at Hamburg Airport.The stock was up 1.24% to $12.29 in after-hours trading.Regeneron, Roche to Collaborate to Scale Up Manufacturing of Antibody Cocktail For COVID-19 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Roche Holdings AG's (OTC: RHHBY) Genentech unit announced a collaboration to develop REGN-COV2, the former's investigational antiviral antibody combination.REGN-COV2 provides a treatment option for people already experiencing symptoms of COVID-19, and also has the potential to prevent infection in people exposed to the virus, the companies said. This collaboration is expected to increase supply of REGN-COV2 to at least three and a half times the current capacity, with the potential for even further expansion.Albireo To Shelve NASH Study After Mixed Results From Phase 2 Proof-of-concept Study Albireo Pharma Inc (NASDAQ: ALBO) said the Phase 2 proof-of-concept study that evaluated its elobixibat for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis achieved the primary endpoint of reduction of low-density lipoprotein cholesterol but did not achieve proof-of-concept for other key NASH measures.Elobixibat is an ileal bile acid transporter inhibitor currently approved in Japan for chronic constipation."Based on the results of this study, we have made the decision not to pursue further development of elobixibat in NASH," said Ron Cooper, CEO of Albireo.Earnings Supernus Pharmaceuticals Inc (NASDAQ: SUPN) reported a 21% year-over-year increase in second-quarter revenues to $126.73 million, and earnings per share climbed from 61 cents to 65 cents, ahead of the 42-cent per share consensus estimate. The company reinstated its fiscal year 2020 guidance and updated it, to reflect the acquisition of the PD products.The stock rose 2.67% to $25.72 in after-hours trading.Offerings Eyenovia Inc (NASDAQ: EYEN) said it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the proposed offering are to be sold by the company.The stock plummeted 16.93% to $3.73 in after-hours trading.On The Radar IPOs La Jolla, California-based InhibRx, a clinical-stage biotechnology company with a pipeline of novel biologic therapeutic candidates, with particular focus on oncology, priced its upsized initial public offering, or IPO, of 6 million shares of its common stock at $17, the mid-point of the estimated price range of $16-$18. The shares are to be listed on the Nasdaq under the ticker symbol INBX.Harmony Biosciences Holdings Inc, a Plymouth, Pennsylvania-based commercial-stage pharmaceutical company focused on innovative therapies for patients living with rare neurological disorders, priced its upsized IPO of 5.35 million shares of its common stock at $24, above the estimated price range of $20-$23. The shares will be listed on the Nasdaq under the ticker symbol HRMY.See more from Benzinga * The Daily Biotech Pulse: Poseida's Phase 1 Study Placed On Clinical Hold, Orphan Drug Designation For Krystal Biotech, Tiziana's Patent Award * The Week Ahead In Biotech: Spotlight On Gilead, BioMarin FDA Decisions, IPOs * The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/19/2020
|
Accelerate Diagnostics Pops 10% On US Emergency Use Nod For Covid-19 Testing
- Shares in Accelerate Diagnostics surged almost 10% in extended market trading after the company said the US Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for its COVID-19 antibody testing system.The stock soared to $16.30 in after-market trading on Tuesday. Accelerate Diagnostics (AXDX) said that following the FDA designation it will market and commercialize its COVID-19 serology-based testing platform. The MS-Fast system and BioCheck SARS-CoV-2 chemiluminescence tests process human serum samples in 30 minutes to detect antibodies that indicate recent or prior COVID-19 infection."This EUA will allow for more widespread adoption of the MS-Fast serology-based COVID-19 antibody testing platform,” Jack Phillips, Accelerate Diagnostics' CEO said. “Serology testing is an important tool in the fight against COVID-19, as it enables the demographic and geographic surveillance necessary to guide an appropriate response to the current pandemic.”Phillips added that the FDA approval marks the next phase in the company’s plan to make a simple-to-use, scalable platform for COVID-19 serology testing available to all laboratories.The BioCheck SARS-CoV-2 IgM and IgG Combo Test targets the S1 protein, which is the major antigen of the novel coronavirus. The S1 protein has the fewest similarities to other coronaviruses, which allows for a lower probability of false positives due to cross reactivity, the company said.“The S1 protein is also the primary target for the leading COVID-19 vaccines candidates, which are being developed to neutralize antibodies that can block the virus from infecting healthy cells,” said Shelley Campeau, Accelerate Diagnostics' Clinical Trials Manager. “Several other EUA approved tests target the nucleocapsid (N) protein, but we believe the S1 protein antibodies are more likely to be protective against infection and are thus a more clinically relevant marker."AXDX shares are down 12% on a year-to-date basis mainly due to profit-taking over the past month.Looking ahead, the two analysts covering the stock see room for more upside. Piper Sandler analyst Rachel Vatnsdal earlier this month raised the stock’s price target to $18 from $14 implying 21% upside potential and reiterated a Buy rating. Craig-Hallum analyst Alexander Nowak this month upgraded AXDX to Buy from Hold with a price target of $20. (See Accelerate Diagnostics’ stock analysis at TipRanks)Meanwhile, the average price target of $19 suggests room for 28% share appreciation over the coming year.Related News: Sorrento Dives 14% In Extended Trading After CFO Ousted Pfizer Inks Deal To Manufacture Gilead’s Covid-19 Remdesivir Treatment Krystal’s ‘Promising’ Cystic Fibrosis Drug Scores Orphan Designation More recent articles from Smarter Analyst: * Agilent Falls In Pre-Market As Quarterly Sales Miss; Oppenheimer Says Hold * Australia Inks Deal With AstraZeneca For Supply Of Covid-19 Vaccine Candidate * Verona Up 10% On Lung Trial Kick Off; Analyst Initiates Stock At ‘Buy’ * Etsy Declares $650M Convertible Note Offering; Stock Up 200% YTD
- 08/19/2020
|
Accelerate Diagnostics Announces FDA Emergency Use Authorization for COVID-19 Antibody Testing System
- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) and BioCheck, Inc., a privately-held San Francisco-based company focused on in vitro diagnostics, today announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the BioCheck SARS-CoV-2 IgM and IgG Combo Test and fully-automated MS-Fast instrument.
- 08/18/2020
|
Reata Slips On Update And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:RETA)
- Reata Slips on operational updates including omaveloxolone setback. Seelos receives FDA nod for Phase IIb/III trial.
- 08/11/2020
|
Global Human Papilloma Virus (HPV) Tests Market 2015-2030 Featuring Hologic, Roche Diagnostics, Qiagen, Biocare Medical, Abbott Laboratories and Others - ResearchAndMarkets.com
|
Global Market Analysis and Forecast Model for Hepatitis C Tests (In Vitro Diagnostics) with COVID-19 Impact Analysis - ResearchAndMarkets.com
|
Opdivo® (nivolumab) Plus Yervoy® (ipilimumab) Demonstrates Durable Survival Benefit vs. Chemotherapy in Patients with Previously Untreated Malignant Pleural Mesothelioma
- Opdivo Plus Yervoy Demonstrates Durable Survival Benefit vs. Chemotherapy in Patients with Previously Untreated Malignant Pleural Mesothelioma
- 08/08/2020
|
Insights on the Global Antimicrobial Susceptibility Testing Market 2020-2024 | COVID-19 Analysis, Drivers, Restraints, Opportunities and Threats | Technavio
- The Global Antimicrobial Susceptibility Testing Market will grow by USD 900.75 mn during 2020-2024
- 08/07/2020
|
Global HIV Tests Market: Impact of COVID-19 for 2020 and Beyond - ResearchAndMarkets.com
|
STERIS plc (STE) CEO Walter Rosebrough on Q1 2021 Results - Earnings Call Transcript
- STERIS plc (NYSE:STE) Q1 2021 Results Conference Call August 03, 2020 10:00 AM ET Company Participants Julie Winter - Investor Relations Walter Rosebrough - President and Chief Executive Officer Michael Tokich - Senior Vice President and Chief Financial Officer Daniel Carestio - Senior Vice President and Chief Operating Officer Conference Call Participants David Turkaly - JMP Securities Christopher Cooley - Stephens Inc Michael Matson - Needham and Company Lawrence Keusch - Raymond James Matthew Mishan - KeyBanc Capital Markets Presentation Operator Good day, and welcome to the STERIS PLC First Quarter Fiscal 2021 Conference Call and Webcast.
- 08/04/2020
|
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
- Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
- 08/02/2020
|
Accelerate Diagnostics (AXDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/30/2020
|
Puma Biotechnology Announces Publication of Results from Phase II SUMMIT Trial Evaluating Neratinib in HER2-Mutant, Metastatic Cervical Cancers
- Puma Biotechnology's P 2 SUMMIT trial results of neratinib in HER2-Mutant, metastatic cervical cancers were published online in Gynecologic Oncology.
- 07/27/2020
|
Need To Know: Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Insiders Have Been Buying Shares
- We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
- 07/17/2020
|
Accelerate Diagnostics Schedules Call to Review Second Quarter 2020 Results
- Accelerate Diagnostics, Inc. announced today that management will host a conference call on Thursday, August 6, 2020 at 4:30 p.m. Eastern Time to review 2020 second quarter financial results.
- 07/16/2020
|
Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Malaysia for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer
- Puma Biotechnology's licensing partner Specialised Therapeutics Asia received authorization to market NERLYNX in Malaysia.
- 07/16/2020
|
AST Private Company Solutions Announces Partnership with Fund Administration Leader Standish Management
- AST Private Company Solutions™ (AST PCS) today announced its latest strategic partnership with Standish Management, a leading fund administration prov
- 07/14/2020
|
$2.47 Million in Sales Expected for Accelerate Diagnostics Inc (NASDAQ:AXDX) This Quarter
- Wall Street analysts predict that Accelerate Diagnostics Inc (NASDAQ:AXDX) will announce sales of $2.47 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Accelerate Diagnostics’ earnings. The lowest sales estimate is $2.25 million and the highest is $2.70 million. Accelerate Diagnostics reported sales of $1.81 million during the […]
- 07/13/2020
|
Arsenal Supporters' Trust seek assurances from club over new loan deal
- The Arsenal Supporters’ Trust have called on the club to provide more information after owners Kroenke Sports & Entertainment (KSE) provided a loan to pay bonds held by investment companies. Financial analysis provided by the AST revealed last month that Arsenal had £144million of remaining debt to bondholders, but that will now be paid off and replaced by another loan which has been taken out by KSE.
- 07/10/2020
|
How do I select an application security testing solution for my business? - Help Net Security
- To select the perfect application security testing solution for your business, you need to think about an array of details.
- 07/08/2020
|
Ast Groupe :
Déclaration des transactions sur actions propres réalisées du 29 juin 2020 au 05 juillet 2020 | Zone bourse
|
Accelerate Diagnostics Inc (NASDAQ:AXDX) Given Consensus Rating of “Buy” by Analysts
- Shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) have received an average rating of “Buy” from the six ratings firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 12-month […]
- 07/07/2020
|
Ipsen : Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-Small Cell Lung Cancer and Metastatic Castration-Resistant Prostate Cancer | MarketScreener
|
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-Small Cell Lung Cancer and Metastatic Castration-Resistant Prostate Cancer
- Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), today announced it will join the Exelixis and Roche clinical collaboration and participate in the
- 07/02/2020
|
Eaton Vance : Certain Eaton Vance Closed-End Funds Announce Telephonic Annual Meeting Of Shareholders On July 16, 2020 | MarketScreener
|
A property investment like no other available in Cheltenham
- Your chance to own this incredible 11-bedroom regency-style building
- 07/01/2020
|
Can-Fite Announces Final Data Analysis from Phase II NASH Study:
Highly Significant and Sustained Reduction in Liver Fat Volume Throughout Study Period
- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that addre
- 06/30/2020
|
Global Antimicrobial Susceptibility Testing Market to 2024 - Featuring Bruker, Danaher & Merck Among Others - ResearchAndMarkets.com
|
Accelerate Diagnostics Inc (AXDX): Hedge Funds Are Snapping Up
- Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
- 06/25/2020
|
|
|
Clinical Laboratory Business Showing Signs of Improvement, Says New Survey by Kalorama Information
- Healthcare Publisher, Kalorama Information, shares recent trends observed from its ongoing study monitoring the impact of COVID-19 on clinical labs.
- 06/25/2020
|
PAYPOINT PLC : Détachement de dividende final | Zone bourse
|
Merck : FDA Approves Merck's KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation | MarketScreener
|
Take a look at this stunning tipi bar coming to York this summer
- THOR's tipi and garden will be running in a socially distant manner
- 06/24/2020
|
Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual
- Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual
- 06/24/2020
|
Ast Groupe :
Déclaration des transactions sur actions propres réalisées du 15 juin 2020 au 21 juin 2020 | Zone bourse
|
Baum drohte in Watzelsdorf abzubrechen
|
Insider Weekends: Charles Davis Purchases $56 Million Worth Of AXIS Capital
- Insider buying doubled last week. Notable Insider Buys: AXIS Capital Holdings Limited, HC2 Holdings, Inc., Accelerate Diagnostics, Inc., Liquidity Services, Inc
- 06/22/2020
|
How to secure software in a DevOps world - Help Net Security
- The COVID-19 pandemic and its impact on the world has made a growing number of people realize how many of our everyday activities depend on software. We
- 06/22/2020
|
Merck : European Medicines Agency Validates Application for BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma | MarketScreener
|
Merck’s KEYTRUDA® (pembrolizumab) Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Whose Tumors Express PD-L1 (CPS ≥10)
- KEYTRUDA® Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- 06/22/2020
|
Sindacati Ast incontrano parlamentari - Umbria
- Prosegue la mobilitazione dei sindacati sulla situazione dell'Ast di Terni dopo l'annuncio da parte
di ThyssenKrupp della ricerca di nuovi partner o di una possibile cessione. (ANSA)
- 06/21/2020
|
Accelerate Diagnostics Target of Unusually High Options Trading (NASDAQ:AXDX)
- Accelerate Diagnostics Inc (NASDAQ:AXDX) was the target of unusually large options trading activity on Thursday. Traders purchased 1,713 put options on the stock. This represents an increase of 1,416% compared to the typical daily volume of 113 put options. In other news, Director Jack W. Schuler bought 95,492 shares of the stock in a transaction […]
- 06/20/2020
|
The Global Cell Isolation/Cell Separation Market is expected to grow from USD 6,356.88 Million in 2019 to USD 14,485.68 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 14.71%
- Market Segmentation & Coverage: This research report categorizes the Cell Isolation/Cell Separation to forecast the revenues and analyze the trends in each of the following sub-markets:
- 06/19/2020
|
AST Private Company Solutions Links with Liquidity Financing Investment Fund Liquid Stock | | IT Business Net
- MENLO PARK, Calif.--(BUSINESS WIRE)--AST Private Company Solutions™ (AST PCS) today introduced a new strategic partnership with Liquid Stock, the venture capital-like investment fund providing bespoke
- 06/18/2020
|
AST Private Company Solutions : Links with Liquidity Financing Investment Fund Liquid Stock
|
STAR BULK PROVIDES DETAILS ON THE DELISTING PROCESS FROM OSLO BØRS, DEREGISTRATION FROM THE VPS AND CONTINUED TRADING ON NASDAQ UNDER THE SYMBOL 'SBLK'
|
The biotech Inventiva announced the success of its NASH treatment
- In terms of safety of use, the profile of the molecule appeared to be "globally favorable" and in line with the observations of previous clinical studies.
- 06/17/2020
|
6 Stocks That Could Run Higher. Targets To Watch
- Stocks Analysis by Harry Boxer covering: Bed Bath & Beyond Inc, Target Corporation, United States Steel Corporation, Celsion Corp. Read Harry Boxer's latest article on Investing.com
- 06/17/2020
|
For airport, power network and toll road stocks the outlook is 'patchy' - Stockhead
- The outlook for toll roads, airports, gas pipelines and electricity networks is likely to be patchy until a COVID-19 vaccine is found, which at the very earliest could be in mid-2021. Energy networks such as Spark Infrastructure (ASX:SKI) are “highly resilient” and toll roads such as Transurban (ASX:TCL) should see traffic volumes return to normal …
- 06/16/2020
|
Almost all 200 stocks made gains this morning: ASX tracking 3.2% higher at noon
- 16 Jun 2020 - The ASX shot up at the open and is now tracking almost 3.2% higher at noon. Almost all the top 200 stocks have made gains today. Viva Energy saw their shares rise today after releasing their underlying net profit for the six months to June to be between $20 million and $50 million compared with $50.9 million a year ago. Village Roadshow (ASX:VRL) has extended by two weeks the exclusivity period for its discussions with private equity firm BGH Capital.
- 06/16/2020
|
STERIS Plc.: Positive Long-Term Outlook Supports Dividend Growth Profile (NYSE:STE)
- Steris reported a record fiscal year for earnings supported by its leadership position in sterilization products and services. The company expects some near-ter
- 06/15/2020
|
Alice Feeney’s ‘His & Hers’ Thriller Novel In Works For TV From Jessica Chastain’s Freckle Films, Kristen Campo & Endeavor Content
- Alice Feeney’s (Sometimes I Lie) latest thriller novel His & Hers is in the works for the small screen. Jessica Chastain’s Freckle Films, Kristen Campo (The Killing, The L- Word), and End…
- 06/15/2020
|
Inventiva sa : À l'opposé des résultats de Genfit, la biotech Inventiva signe un succès clinique dans la NASH
- (BFM Bourse) - La biotech bourguignonne a annoncé lundi le succès sur différents critères d'efficacité de sa molécule lanifibranor pour soigner les …
- 06/15/2020
|
Ast Groupe :
Déclaration des transactions sur actions propres réalisées du 8 juin 2020 au 14 juin 2020 | Zone bourse
|
These 2 Stocks Are Cleaning Up Thanks To Medical Mask Sterilization. Are They Buys? | The Motley Fool
- Steris and Fortive are on the rise, thanks in part to their medical devices used to decontaminate N95 or N95-equivalent respirators.
- 06/15/2020
|
Faruqi & Faruqi, LLP is Investigating Accelerate Diagnostics, Inc. (AXDX) on Behalf of its Shareholders
- NEW YORK, June 15, 2020 -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential misconduct at Accelerate Diagnostics, Inc. (“Accelerate.
- 06/15/2020
|
Insider Weekends: Director Of Accelerate Diagnostics Adds To His Stock
- Insider buying decreased significantly last week. Notable Insider Buys: Accelerate Diagnostics, Inc., Keurig Dr Pepper Inc., Vishay Precision Group, Inc., Corte
- 06/15/2020
|
Eli Lilly and : Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients | MarketScreener
|
Community Bank System, Inc. Completes Merger with Steuben Trust Corporation and Enhances Western New York Presence
- Community Bank System, Inc. Completes Merger with Steuben Trust Corporation and Enhances Western New York Presence
- 06/15/2020
|
How to obtain NBA statistics for your favorite players with a Python function
- Query over 60 years of NBA stats directly from the command line
- 06/14/2020
|
Crypto Tidbits: Bitcoin Fails at $10k, Ethereum Coins Explode, Coinbase Looks to Add 18 Altcoins | NewsBTC
- Another week, another round of Crypto Tidbits.
- 06/13/2020
|
The Blackpool street where several shops are up for sale
- Three shops are now on offer in Bond Street, South Shore, after failing to sell at auction.
- 06/12/2020
|
11-jähriger Bub verletzt sich bei Sturz von Baum
- Bei einem Spielplatz in Solothurn stürzte am Freitagmorgen ein Kind von einem Baum und verletzte sich. Der Junge musste mit einem Rettungshelikopter ins Spital geflogen werden.
- 06/12/2020
|
Proclamato stato agitazione all'Ast - Umbria
- È stato di agitazione all'Ast di Terni: a proclamarlo, nella tarda serata di ieri, sono state
congiuntamente le segreterie territoriali dei metalmeccanici e le rsu dello stabilimento, nel corso
di una riunione straordinaria convocata dopo un incontro, nel ... (ANSA)
- 06/12/2020
|
In Vitro Diagnostics (IVD) Products and Test Market Size 2020 : Growth Factors, Business OpportunitySegmentation and Forecast to 2026 Research Report by implies of Market Growth Reports
- Jun 12, 2020 (The Expresswire) --
Global “In Vitro Diagnostics (IVD) Products and Test Market” analysis 2020 covers the entire supply chain, focusing on...
- 06/12/2020
|
Merck Provides Update on Phase 3 KEYNOTE-361 Trial Evaluating KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy in Patients with Advanced or Metastatic Urothelial Carcinoma
- Merck Provides Update on Phase 3 KEYNOTE-361 Trial Evaluating KEYTRUDA® (pembrolizumab) in Patients with Advanced or Metastatic Urothelial Carcinoma
- 06/09/2020
|
Analysis of open source iOS apps
- How smelly is the code and what about testing?
- 06/08/2020
|
Let’s Build a Linux Shell — Part I
- Since the early days of Unix, the shell has been an important part of the user’s interface with the operating system. The first Unix shell…
- 06/08/2020
|
AbbVie Presents Data Showing RINVOQ™ (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Head-to-Head Study Versus ORENCIA (abatacept) in Rheumatoid Arthritis Patients
- NORTH CHICAGO, Ill., June 6, 2020 /PRNewswire via COMTEX/ --
NORTH CHICAGO, Ill., June 6, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global...
- 06/06/2020
|
Einfache und köstliche Rezepte für Schlangenbrot - Blick
- Viele lieben es, beim Grillieren oder am Lagerfeuer an einem Ast selbst gemachtes Schlangenbrot zu backen. Das weckt Kindheitserinnerungen. Ein Vergnügen für Klein und Gross!
- 06/05/2020
|
AST Private Company Solutions Leverages Box Platform to Power Astrella and Transform the Private Ownership Market
- AST Private Company Solutions™ (AST PCS) today announced that it is leveraging Box Platform to power AST PCS’s new Astrella™ capitalization (cap) tabl
- 06/03/2020
|
Vorher-Nachher-Vergleich - Garten-Umgestaltungen für mehr Biodiversität mit Wow-Effekt
- Vorhang auf für ein paar ausgewählte «Mission B»-Projekte, dokumentiert mit Vorher-Nachher-Bildern.
- 06/02/2020
|
Market Research Report Of India Diagnostic Laboratories, Industry Research Report
- The report covers Evaluation Study India Diagnostic Laboratories Market, Write An Evaluation Report On India Diagnostic Laboratories Market.
- 06/02/2020
|
India Diagnostic Laboratories Market, India Diagnostic Laboratories Industry
- The report covers India Diagnostic Laboratories Market, India Diagnostic Laboratories Industry, Laboratories Market Research Report.
- 06/02/2020
|
Pirate operators can have you up in smoke warns AST
- Allowing untrained professionals to service and maintain fire protection systems will not only dent a puts employees at great risk warns warns AST.
- 06/02/2020
|
Create a Custom Web Editor Using TypeScript, React, ANTLR, and Monaco Editor
- Part 1: Build a web editor with syntax colorization
- 06/01/2020
|
Cell Separation by Membrane Filtration Technology Market Insight & Future Assessment for the Period 2020 - 2029
- Jun 01, 2020 (AmericaNewsHour) --
The research study on Global Cell Separation by Membrane Filtration Technology market 2019 presents an extensive analysis...
- 06/01/2020
|
Die sieben heissesten Fragen des Hockey-Sommers - Blick
- Revolution oder sanfte Reformen. Im Schweizer Eishockey werden in den nächsten Monaten die Weichen für die Zukunft gestellt.
- 05/31/2020
|
Takeda präsentiert Daten aus dem klinischen Studienprogramm ICLUSIG® (Ponatinib) mit möglichen Auswirkungen auf die Behandlungspraxis für die chronische Phase der CML
- Wie Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) heute mitteilte, werden Zwischenanalysedaten aus der Phase-2-Studie OPTIC (Optimizing Po
- 05/31/2020
|
Accelerate Diagnostics (AXDX) Moves to Strong Buy: Rationale Behind the Upgrade
- Accelerate Diagnostics (AXDX) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 05/29/2020
|
IMFINZI® (durvalumab) Showed a Sustained Overall Survival Benefit in 1st-Line Extensive-Stage Small Cell Lung Cancer in the Phase III CASPIAN Trial
- Detailed results from an updated analysis of the Phase III CASPIAN trial showed AstraZeneca’s IMFINZI in combination with a choice of chemotherapies,
- 05/29/2020
|
Polish and Baltic states’ power grid operators ask EU for €1.2bn to fund syncing of their energy systems
- The Polish power grid operator PSE, together with its peers from Estonia, Latvia, and Lithuania, jointly filed for €1.2bn of EU funding to advance ...
- 05/27/2020
|
How Accelerate Diagnostics (AXDX) Stock Stands Out in a Strong Industry
- Accelerate Diagnostics (AXDX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 05/26/2020
|
Unwetter forderte die Feuerwehren
|
Edited Transcript of AXDX earnings conference call or presentation 7-May-20 8:30pm GMT
- Q1 2020 Accelerate Diagnostics Inc Earnings Call
- 05/21/2020
|
AST Revolutionizes Private Market Ownership Data Management with Launch of Astrella™ Platform
- AST, through its Private Company Solutions (AST PCS) business unit, today launched its innovative software-as-a-service (SaaS)-based Astrella solution
- 05/21/2020
|
ASX claws back from a drop at the open: ASX closed 0.2% higher
- 20 May 2020 - The ASX dropped at the open then managed to claw back up to close 0.2% higher. Shares in EML payments (ASX:EML) rose today, as shares in Ausnet Services (ASX:AST) dropped. As for the sectors today Infotech led the day and Utilities fell lower. Aspen Group (ASX:APZ) has entered into a contract to acquire a partially refurbished co-living community at in Newcastle, NSW.
- 05/20/2020
|
Polizei-Ermittlungen nach Rätsel um Blutspur im Wald
- Am Montagabend informierte ein Zeuge die deutschen Polizei, nachdem er in einem Wald nördlich von Rheinfelden (D) eine Blutspur sowie ein Auto auf einem Waldweg gesehen hat. Eine Zeugin klärte den Fall wenig später auf.
- 05/19/2020
|
Ipsen Announces Publication of First Matching-Adjusted Indirect Comparison of Cabometyx® (cabozantinib) Versus regorafenib in Advanced Hepatocellular Carcinoma in Advances in Therapy
- Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that data from the matching-adjusted indirect comparison (MAIC) of Cabometyx® (cabo
- 05/19/2020
|
Ailing icon Thyssenkrupp seeks partners for steel, warship units | MarketScreener
|
Griffin Asset Management, Inc. Buys Accelerate Diagnostics Inc, The Walt Disney Co, Visa Inc, ...
|
Fin a la luna de miel: sindicatos de Zara piden cambiar el plan de desescalada de la empresa
- Después de dos meses de calma, las tensiones han empezado a aparecer entre los representantes de los trabajadores y los responsables de Recursos Humanos de Inditex
- 05/16/2020
|
Compression stockings may not be needed after surgeries
- A new study offers reassurance that many surgery patients can safely be freed from one discomfort of recovery -- wearing compression stockings to prevent blood clots.
- 05/15/2020
|
STERIS' (STE) CEO Walt Rosebrough on Q4 2020 Results - Earnings Call Transcript
- STERIS plc (NYSE:STE) Q4 2020 Earnings Conference Call May 14, 2020 10:00 AM ET Company Participants Julie Winter – Investor Relations Mike Tokich – Senior Vice
- 05/14/2020
|
Congress and Corporations Join Forces To Crush American Small Business | naked capitalism
- Funny how that small business bailout worked.....
- 05/14/2020
|
How to buy Ausnet Services shares | 18 May price A$1.89 | Finder
- Ever wondered how to buy shares in Ausnet Services? We explain how and compare the best share trading platforms. Latest Ausnet Services share price is A$1.89.
- 05/14/2020
|
Bayer and ArcherDX Announce Global Collaboration to Develop Next-Generation Sequencing (NGS)-based Companion Diagnostic (CDx) for VITRAKVI® (larotrectinib)
- Bayer and ArcherDX, Inc. today announced a global collaboration for the development and commercialization of a next-generation sequencing (NGS)-based
- 05/14/2020
|
Annual wage growth slow pre-coronavirus restrictions: The ASX is tracking 0.9% lower
- 13 May 2020 - The ASX dropped at the open as investors evaluate the risk of opening up the economy. It is now tracking almost 0.9 per cent lower at noon. Pilbara Minerals (ASX:PLS) did well today as did shares in Mayne Pharma Group (ASX:MYX). All the sectors are in the red with the communication services are leading the pack. Biotech Mesoblast (ASX:MSB) has successfully completed a capital raising of $138 million.
- 05/13/2020
|
Three-Year Data from CheckMate -227 Confirm Durable, Long-Term Survival Benefit for Opdivo (nivolumab) Plus Yervoy (ipilimumab) vs. Chemotherapy in Metastatic First-Line Non-Small Cell Lung Cancer Patients with PD-L1 ≥1%
- Three-Year Data from CheckMate -227 Confirm Durable, Long-Term Survival Benefit for Opdivo (nivolumab) Plus Yervoy (ipilimumab) vs. Chemotherapy....
- 05/13/2020
|
|
|
Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q1 2020 Results - Earnings Call Transcript
- Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Q1 2020 Results Conference Call May 11, 2020 4:30 PM ET Company Participants Jayne Kauffman - Senior Executive Coor
- 05/12/2020
|
CymaBay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q1 2020 Results - Earnings Call Transcript
- CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Q1 2020 Earnings Conference Call May 11, 2020 04:30 PM ET Company Participants Dan Menold - Vice President, Finance Suj
- 05/12/2020
|
Seattle Genetics Announces the Approval of TUKYSA™ (tucatinib) in Switzerland for the Treatment of Patients with Metastatic HER2-Positive Breast Cancer
- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted approval for TUKYSA™ (tuc
- 05/12/2020
|
U.S. RESEARCH ROUNDUP-Acushnet Holdings, Equity Residential, Fiserv
- Wall Street securities analysts revised their ratings and price targets
on several U.S.-listed companies, including Acushnet Holdings, Equity Residential and Fiserv, on
Monday.
HIGHLIGHTS
* Acushnet Holdings Corp : Stephens raises target price to $27 from $24
* Equity Residential : Evercore ISI raises to in-line from underperform
* Fiserv Inc : Keybanc raises target price to $115 from $108
* GTT Communications Inc : SunTrust Robinson cuts to hold from buy
* UDR Inc : Evercore ISI raises to in-line from underperform
Following is a summary of research actions on U.S. companies reported by Reuters on Monday.
Stock entries are in alphabetical order.
* Abbvie Inc : SVB Leerink raises price target to $122 from $107
* Accelerate Diagnostics Inc : Piper Sandler cuts target price to $14 from $16
* Acushnet Holdings Corp : Compass Point raises TP to $22.25 from $21.50
* Acushnet Holdings Corp : Keybanc raises target price to $31 from $28
* Acushnet Holdings Corp : Stephens raises target price to $27 from $24
* Advance Auto Parts Inc : UBS raises target price to $140 from $135
* AIG : UBS cuts target price to $45 from $49
* Air Lease Corp : Deutsche Bank cuts target price to $36 from $45
* Air Lease Corp : Stephens raises target price to $36 from $30
* Airgain Inc : Northland Capital Markets raises target price to $23
* Alarm.Com Holdings Inc : Credit Suisse cuts target price to $62 from $64
* Albemarle Corp : RBC raises target price to $66 from $64
* Albemarle Corp : SunTrust Robinson cuts target price to $65 from $90
* Allegiant Travel Co : Evercore ISI cuts target price to $95 from $100
* Allscripts Healthcare Solutions : Canaccord Genuity cuts TP to $11 from $13
* Amdocs Ltd : Citigroup cuts price target to $76 from $83
* Amedisys Inc : Raymond James cuts price target to $210 from $225
* Amedisys Inc : UBS cuts target price to $190 from $208
* American Axle & Manufacturing Holdings : Citigroup raises TP to $7.5 from $6
* American Axle & Manufacturing Holdings : RBC raises target price to $7 from $5
* American Homes 4 Rent : Evercore ISI raises target price to $27 from $25
* Ameriprise Financial Inc : RBC raises target price to $155 from $145
* Amerisourcebergen Corp : Deutsche Bank raises target price to $98 from $93
* Amphastar Pharmaceuticals Inc : BMO raises price target to $21 from $20
* Angi Homeservices Inc : Citigroup raises price target to $10 from $6.5
* Aon Plc : Citigroup cuts price target to $230 from $240
* Aon Plc : KBW raises target price to $192 from $184
* Aon Plc : UBS cuts target price to $197 from $202
* Apache Corp : CFRA cuts to sell from hold; raises price target to $9
* Apache Corp : MKM Partners cuts target price by $1 to $19
* Aptiv Plc : Benchmark cuts price target to $87 from $90
* Arch Capital Group Ltd : UBS cuts target price to $39 from $43
* Atara Biotherapeutics Inc : Jefferies cuts target price to $11 from $13
* Athene Holding Ltd : BMO cuts price target to $60 from $63
* Atricure Inc : BTIG raises target price to $56 from $45
* Atricure Inc : Needham raises target price to $63 from $49
* Atricure Inc : Oppenheimer raises price target to $52 from $45
* Atricure Inc : SVB Leerink raises price target to $55 from $50
* Autonation Inc : CFRA cuts price target by $10 to $50
* Avalonbay Communities Inc : Evercore ISI cuts target price to $181 from $189
* Avista Corp : Guggenheim cuts target price to $38 from $39
* Bain Capital Specialty Finance : Citigroup raises price target to $10 from $7.5
* Ball Corp : Citigroup cuts price target to $86 from $89
* Ball Corp : Northland Capital Markets cuts target price to $80
* Baudax Bio Inc : Oppenheimer cuts price target to $14 from $16
* Bellring Brands Inc : Stifel cuts target price to $23 from $25
* BJ's Restaurants Inc : Deutsche Bank raises target price to $27 from $26
* Bloomin' Brands Inc : BMO raises price target to $10 from $9
* Bloomin' Brands Inc : Deutsche Bank raises target price to $15 from $14
* Bloomin' Brands Inc : Guggenheim raises target price to $15 from $11
* Bloomin' Brands Inc : Raymond James cuts target price to $14 from $15
* BP Midstream Partners LP : Mizuho raises target price to $14 from $13
* Broadridge Financial Solutions : Piper Sandler cuts TP to $120 from $124
* Broadridge Financial Solutions : Rosenblatt Securities ups TP to $115 from $101
* Brookfield Infrastructure Partners LP : BMO raises price target to $46 from $45
* Brookfield Infrastructure Partners LP : Scotiabank cuts Tp to $50 from $51
* Brookfield Property Partners LP : Canaccord Genuity cuts TP to $12 from $13
* Brookfield Property Partners LP : CIBC cuts target price to $18 from $20.50
* Brookfield Property Partners LP : RBC cuts target price to $18 from $22
* Bruker Corp : BTIG cuts price target to $50 from $57
* Cabot Oil & Gas Corp : Tudor Pickering Holt cuts to hold from buy
* Calithera Biosciences Inc : Citigroup raises price target to $10 from $7
* Callaway Golf Co : >: Compass Point cuts target price to $17.50 from $20
* Callaway Golf Co : Compass Point cuts target price to $17.50 from $20
* Camden Property Trust : Evercore ISI cuts target price to $98 from $102
* Camden Property Trust : Stifel raises target price to $96 from $91
* Cardtronics Plc : D.A. Davidson cuts target price to $34 from $40
* Cardtronics Plc : SunTrust Robinson raises target price to $29 from $23
* Cargurus Inc : RBC raises target price to $25 from $22
* Carnival : HSBC raises to buy from hold; cuts target price to $15.9 from $45.3
* Carrier Global Corp : Citigroup raises price target to $20 from $17
* Carvana Co : Oppenheimer raises price target to $127 from $95
* Carvana Co : Oppenheimer raises target price to $127 from $95
* Casella Waste Systems Inc : Jefferies raises target price to $56 from $52
* Casella Waste Systems Inc : Raymond James raises target price to $56 from $49
* Casella Waste Systems Inc : Stifel raises target price to $47 from $45
* Cellectis : Citigroup cuts price target to $15 from $16
* Centurylink Inc : SunTrust Robinson cuts target price to $9 from $10
* Ceridian Hcm Holding Inc : Jefferies raises target price to $65 from $60
* Chevron Corp : Independent Research raises target price to $98 from $90; hold
* CNX Resources Corp : Tudor Pickering Holt cuts to hold from buy
* Cognizant Technology Solutions : Evercore ISI cuts target price to $53 from $55
* Cognizant Technology Solutions Corp : HSBC cuts target price to $56 from $70
* Coherus Biosciences Inc : Citigroup cuts price target to $30 from $31
* Conagra Brands Inc : SunTrust Robinson cuts to hold from buy
* Consolidated Edison Inc : Evercore ISI cuts target price to $85 from $86
* Continental Resources : TD Securities raises target price to $14.50 from $13.50
* Cooper Tire & Rubber Co : JP Morgan cuts target price to $29 from $30
* Corporate Office Properties Trust : SunTrust Robinson raises TP to $28 from $26
* Corteva Inc : RBC raises target price to $31 from $27
* Covanta Holding : Stifel raises to hold from sell; raises TP to $9.50 from $6.50
* Crocs Inc : Piper Sandler raises target price to $28 from $24
* Cross Country Healthcare Inc : BMO cuts price target to $8 from $11
* Cryoport Inc : Stephens raises target price to $23 from $21
* CVR Energy Inc : Credit Suisse raises target price to $19 from $16
* Cytomx Therapeutics Inc : Wedbush raises target price to $16 from $11
* Danaher Corp : Evercore ISI raises target price to $175 from $150
* Danaher Corp : RBC raises target price to $173 from $159
* Datadog Inc : RBC raises target price to $50 from $43
* Dentsply Sirona : Barrington Research cuts to market perform from outperform
* Dentsply Sirona Inc : UBS cuts target price to $44 from $59
* Dicerna Pharmaceuticals : SunTrust Robinson raises target price to $33 from $28
* Diebold Nixdorf Inc : JP Morgan raises target price to $7 from $6
* Diebold Nixdorf Inc : JP Morgan raises to neutral from underweight
* Discovery Inc : Rosenblatt Securities cuts price target to $24 from $27
* Dish Network Corp : RBC cuts target price to $32 from $39
* Domtar : D.A. Davidson cuts to neutral from buy; cuts TP to $26 from $44
* Domtar Corp : Scotiabank cuts target price to $29 from $30
* Domtar Corp : TD Securities raises target price to $26 from $22
* E. W. Scripps Co : Benchmark cuts target price to $15 from $24
* E. W. Scripps Co : Guggenheim raises target price to $8 from $6.50
* Edison Intl.
- 05/11/2020
|
Bayer to Present Data from Growing Oncology Portfolio at the ASCO20 Virtual Scientific Program
- Data from Bayer’s growing oncology portfolio will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, ta
- 05/11/2020
|
Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q1 2020 Results - Earnings Call Transcript
- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q1 2020 Earnings Conference Call May 7, 2020 4:30 P.M. ET Company Participants Laura Pierson - Investor Relations Jac
- 05/10/2020
|
Accelerate Diagnostics (AXDX) Q1 2020 Earnings Call Transcript
- Before we begin, it is important to share that information presented during this call may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include projections, statements about our future and those that are not historical facts. All forward-looking statements that are made during this conference call are subject to risks, uncertainties and other factors that could cause our actual results to differ materially.
- 05/10/2020
|
Edited Transcript of AXDX earnings conference call or presentation 7-May-20 8:30pm GMT
- Q1 2020 Accelerate Diagnostics Inc Earnings Call
- 05/08/2020
|
Accelerate Diagnostics Q1 EPS $(0.390) Misses $(0.380) Estimate, Sales $2.342M Beat $2.270M Estimate
|
Accelerate Diagnostics Announces First Quarter Financial Results and Provides COVID-19 Business Updates
- Accelerate Diagnostics, Inc. (NASDAQ: AXDX), today announced financial results for the quarter ending March 31, 2020 and provided a business update regarding the impact of the ongoing COVID-19 pandemic on the Company's operations.
- 05/07/2020
|
Exclusive: U.S. companies got emergency government loans despite having months of cash
- When American companies recently applied for U.S. government loans meant to help small businesses survive the coronavirus crisis, they had to certify they needed the cash to cover basic needs like salaries and rent. The money, up to $10 million, was meant to tide them over for eight weeks.
- 05/07/2020
|
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 6.)
Adverum Biotechnologies Inc...
- 05/07/2020
|
Insider Weekends: Delta Air Lines Insider Buys Stock Even As Buffett Sells
- Insider buying decreased last week. Notable Insider Buys: The Simply Good Foods Company, Accelerate Diagnostics, Inc., Unity Bancorp, Inc., Delta Air Lines, Inc
- 05/04/2020
|
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
- Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
- 05/03/2020
|
Insiders Who Find Their Stock To Be Undervalued - Weekly Update (04/24/20 - 04/30/20)
- Picking the right stocks in this market environment has become increasingly important. Following insider purchases can help investors to outperform the market s
- 05/02/2020
|
Source Capital, Inc. : Announces Change to Virtual Format for the Annual Meeting of Shareholders to be Held on May 11, 2020 | MarketScreener
|
Source Capital, Inc. Announces Change to Virtual Format for the Annual Meeting of Shareholders to be Held on May 11, 2020
- Source Capital, Inc. (“Source” or “Company”) announced today that due to the emerging public health impact of the coronavirus pandemic (COVID-19), the
- 05/02/2020
|
Will Accelerate Diagnostics (AXDX) Report Negative Earnings Next Week? What You Should Know
- Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/30/2020
|
Will Accelerate Diagnostics (AXDX) Report Negative Earnings Next Week? What You Should Know
- Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/30/2020
|
Bank of America Corp DE Sells 7,170 Shares of Accelerate Diagnostics Inc (NASDAQ:AXDX)
- Bank of America Corp DE decreased its holdings in Accelerate Diagnostics Inc (NASDAQ:AXDX) by 21.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 26,352 shares of the medical research company’s stock after selling 7,170 shares during the period. Bank of America Corp DE’s […]
- 04/30/2020
|
Will Accelerate Diagnostics (AXDX) Report Negative Earnings Next Week? What You Should Know
|
Daily Insider Ratings Round Up 4/27/20
- Tables of the top insider purchases and sales filed with the SEC on 4/27/20, based on dollar value. Dollar values often do not equate with significance when it
- 04/29/2020
|
Accelerate Diagnostics Inc (NASDAQ:AXDX) Director Jack W. Schuler Purchases 5,001 Shares
- Accelerate Diagnostics Inc (NASDAQ:AXDX) Director Jack W. Schuler acquired 5,001 shares of the stock in a transaction that occurred on Friday, April 24th. The stock was purchased at an average price of $11.04 per share, for a total transaction of $55,211.04. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, […]
- 04/29/2020
|
Accelerate Diagnostics (NASDAQ:AXDX) Rating Increased to Buy at Zacks Investment Research
- Accelerate Diagnostics (NASDAQ:AXDX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Monday, Zacks.com reports. The firm currently has a $12.00 target price on the medical research company’s stock. Zacks Investment Research‘s price target would indicate a potential upside of 9.39% from […]
- 04/29/2020
|
The Lakers Got Federal Aid and Your Corner Shop Didn’t
- By Timothy L. O’Brien(Bloomberg Opinion) — In the pre-coronavirus days, the Los Angeles Lakers was one of the most valuable and profitable sports franchises on the planet. Forbes estimated la…
- 04/28/2020
|
The Lakers Got Federal Aid and Your Corner Shop Didn’t
- (Bloomberg Opinion) -- In the pre-coronavirus days, the Los Angeles Lakers was one of the most valuable and profitable sports franchises on the planet. Forbes estimated last year that the team earned $147 million in 2018 and would fetch about $3.7 billion in a sale. A trust controlled by the children
- 04/28/2020
|
Insider Weekends: Markets Continue To Buck Economic Headwinds
- Insider buying decreased last week. Notable Insider Buys: Halliburton Company, Accelerate Diagnostics, Inc., AT&T Inc., Groupon, Inc., Morgan Stanley. Notable I
- 04/27/2020
|
Daily Insider Ratings Round Up 4/24/20
- Tables of the top insider purchases and sales filed with the SEC on 4/24/20, based on dollar value. Dollar values often do not equate with significance when it
- 04/27/2020
|
Fly Insider: Accelerate Diagnostics, Abbott among week's notable insider trades MYOV;AIMT;AXDX;CFG;VOXX;KMB;PGNY;EBS;ABT;ACAD
- Fly Insider: Accelerate Diagnostics, Abbott among week's notable insider trades MYOV AIMT AXDX CFG VOXX KMB PGNY EBS ABT ACAD
- 04/27/2020
|
Accelerate Diagnostics Inc (NASDAQ:AXDX) Director Jack W. Schuler Purchases 157,688 Shares
- Accelerate Diagnostics Inc (NASDAQ:AXDX) Director Jack W. Schuler purchased 157,688 shares of the stock in a transaction that occurred on Wednesday, April 22nd. The stock was purchased at an average price of $9.47 per share, for a total transaction of $1,493,305.36. The acquisition was disclosed in a filing with the SEC, which is available at […]
- 04/25/2020
|
Accelerate Diagnostics Inc (NASDAQ:AXDX) Shares Purchased by Geode Capital Management LLC
- Geode Capital Management LLC lifted its position in Accelerate Diagnostics Inc (NASDAQ:AXDX) by 1.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 382,510 shares of the medical research company’s stock after acquiring an additional 5,549 shares during the period. Geode […]
- 04/25/2020
|
Daily Insider Ratings Round Up 4/23/20
- Tables of the top insider purchases and sales filed with the SEC on 4/23/20, based on dollar value. Dollar values often do not equate with significance when it
- 04/24/2020
|
Jack W. Schuler Purchases 59,357 Shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) Stock
- Accelerate Diagnostics Inc (NASDAQ:AXDX) Director Jack W. Schuler purchased 59,357 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The shares were purchased at an average cost of $9.40 per share, for a total transaction of $557,955.80. The transaction was disclosed in a document filed with the SEC, which is […]
- 04/24/2020
|
Daily Insider Ratings Round Up 4/22/20
- Tables of the top insider purchases and sales filed with the SEC on 4/22/20, based on dollar value. Dollar values often do not equate with significance when it
- 04/23/2020
|
Accelerate Diagnostics Inc (NASDAQ:AXDX) Given Consensus Recommendation of "Hold" by Analysts
- Shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) have received an average rating of “Hold” from the seven research firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating on the company. The […]
- 04/23/2020
|
Accelerate Diagnostics (NASDAQ:AXDX) Rating Lowered to Hold at Zacks Investment Research
- Accelerate Diagnostics (NASDAQ:AXDX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports. According to Zacks, “Accelerate Diagnostics, Inc. is focused on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company is developing BACcel(TM) […]
- 04/23/2020
|
Accelerate Diagnostics (NASDAQ:AXDX) Stock Price Up 7.3% on Insider Buying Activity
- Accelerate Diagnostics Inc (NASDAQ:AXDX) shares rose 7.3% during mid-day trading on Wednesday following insider buying activity. The company traded as high as $9.88 and last traded at $9.67, approximately 533,508 shares traded hands during trading. An increase of 45% from the average daily volume of 367,222 shares. The stock had previously closed at $9.01. Specifically, […]
- 04/23/2020
|
Accelerate Diagnostics (AXDX) Moves to Buy: Rationale Behind the Upgrade
- Accelerate Diagnostics (AXDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 04/22/2020
|
Accelerate Diagnostics (AXDX) Moves to Buy: Rationale Behind the Upgrade
- Accelerate Diagnostics (AXDX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 04/22/2020
|
Corporate Insiders Pull the Trigger on These 5 Stocks
- Market watchers are looking to the insiders, hoping insights from their activity can steer them towards returns from these stocks to buy.
- 04/22/2020
|
Bank of New York Mellon Corp Acquires 5,220 Shares of Accelerate Diagnostics Inc (NASDAQ:AXDX)
- Bank of New York Mellon Corp increased its holdings in shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) by 4.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 119,111 shares of the medical research company’s stock after buying an additional 5,220 shares during […]
- 04/22/2020
|
Pre & Post COVID-19 Market Estimates-Global Antimicrobial Susceptibility Testing Market 2020-2024 | Evolving Opportunities with Accelerate Diagnostics Inc. and ALIFAX Srl | Technavio
- The antimicrobial susceptibility testing market size has the potential to grow by USD 900.75 million during 2020-2024.
- 04/22/2020
|
Accelerate Diagnostics (NASDAQ:AXDX) Stock Rating Upgraded by BidaskClub
- Accelerate Diagnostics (NASDAQ:AXDX) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday, BidAskClub reports. A number of other equities analysts have also recently issued reports on AXDX. Zacks Investment Research cut Accelerate Diagnostics from a “buy” rating to a “hold” rating […]
- 04/22/2020
|
Zacks Investment Research Upgrades Accelerate Diagnostics (NASDAQ:AXDX) to "Buy"
- Accelerate Diagnostics (NASDAQ:AXDX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Monday, Zacks.com reports. The brokerage currently has a $11.00 target price on the medical research company’s stock. Zacks Investment Research‘s price objective indicates a potential upside of 22.09% from the […]
- 04/22/2020
|
Accelerate Diagnostics (AXDX) Moves to Buy: Rationale Behind the Upgrade
|
Accelerate Diagnostics Inc (NASDAQ:AXDX) Shares Bought by Goldman Sachs Group Inc.
- Goldman Sachs Group Inc. grew its holdings in shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) by 9.0% during the 4th quarter, HoldingsChannel.com reports. The firm owned 51,828 shares of the medical research company’s stock after buying an additional 4,280 shares during the period. Goldman Sachs Group Inc.’s holdings in Accelerate Diagnostics were worth $876,000 as of […]
- 04/19/2020
|
12 Short Squeeze Candidates To Watch
- One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a list of potential short squeeze stocks based on their high borrow rates.A stock borrow fee is the percentage
- 04/17/2020
|
Arizona diagnostics company collaborates on coronavirus antibody tests
- Arizona company Accelerate Diagnostics Inc. is teaming up with BioCheck Inc. to fight the novel coronavirus with a collaboration to distribute antibody tests in the U.S. and abroad.
- 04/16/2020
|
